<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The islet in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) is characterized by a deficit in β-cells, increased β-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and extracellular amyloid deposits derived from islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (IAPP) </plain></SENT>
<SENT sid="1" pm="."><plain>In the absence of longitudinal studies, it is unknown if the low β-cell mass in T2DM precedes <z:mp ids='MP_0002055'>diabetes</z:mp> <z:hpo ids='HP_0003674'>onset</z:hpo> (is a risk factor for <z:mp ids='MP_0002055'>diabetes</z:mp>) or develops as a consequence of the disease process </plain></SENT>
<SENT sid="2" pm="."><plain>Although <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> is a risk factor for T2DM, most individuals who are insulin resistant do not develop <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>By inference, an increased β-cell workload results in T2DM in some but not <z:hpo ids='HP_0000001'>all</z:hpo> individuals </plain></SENT>
<SENT sid="4" pm="."><plain>We propose that the extent of the β-cell mass that develops during childhood may underlie subsequent successful or failed adaptation to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in later life </plain></SENT>
<SENT sid="5" pm="."><plain>We propose that a low innate β-cell mass in the face of subsequent <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> may expose β-cells to a burden of insulin and IAPP biosynthetic demand that exceeds the cellular capacity for protein folding and trafficking </plain></SENT>
<SENT sid="6" pm="."><plain>If this threshold is crossed, intracellular toxic IAPP membrane permeant oligomers (cylindrins) may form, compromising β-cell function and inducing β-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
</text></document>